In patients suspected of preeclampsia, the sFlt-1/PlGF ratio is a well-established biomarker for the diagnosis of preeclampsia.13,18,20,23 Our study has prospectively assessed the clinical impact of incorporating this ratio into a broader risk assessment tool focusing on complications. This evidence concerns the gene PGF and preeclampsia.